Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zhengye Biotechnology Holding Ltd. ( (ZYBT) ) just unveiled an announcement.
On May 20, 2025, Zhengye Biotechnology Holding Limited received a NASDAQ Delinquency Notice for failing to timely file its Form 20-F for the fiscal year ended December 31, 2024. The company announced this on May 23, 2025, and has 60 days to submit a compliance plan to regain adherence to NASDAQ rules. This notice does not immediately affect the company’s stock listing on the Nasdaq Capital Market.
More about Zhengye Biotechnology Holding Ltd.
Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer based in Jilin, China, specializing in the research, development, manufacturing, and sales of vaccines for livestock. The company operates through Jilin Zhengye Biological Products Co., Ltd., offering 44 veterinary vaccines for various animals such as swine, cattle, goats, sheep, poultry, and dogs. Their products are distributed across 28 provincial regions in China and exported to countries like Vietnam, Pakistan, and Egypt. The company has three GMP veterinary vaccine production floors and a team of 49 experienced employees.
Average Trading Volume: 463,164
For a thorough assessment of ZYBT stock, go to TipRanks’ Stock Analysis page.